Matrix metalloproteinases and atherosclerosis;Metaloproteinazy w miazdzycy naczyń krwionośnych

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 65, Issue , 2011, Pages 16-27

  Fic, Piotr ^a   Zakrocka, Izabela ^b   Kurzepa, Jacek ^b   Stepulak, Andrzej ^b,c  

^a Wyszy skiego   (Poland)

^b Katedra i Zak ad Biochemii i Biologii Molekularnej   (Poland)

^c Szpital MSWiA   (Poland)

Author keywords

Atherosclerosis; Matrix metalloproteinases; Plaque rupture

Indexed keywords

BIOLOGICAL MARKER; MATRIX METALLOPROTEINASE;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD; HUMAN; METABOLISM; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; HUMANS; MATRIX METALLOPROTEINASES; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS;

EID: 79958781233     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.931536     Document Type: Review

References (105)

1. Abilleira S., Bevan S., Markus H.S.: The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J. Med. Genet., 2006; 43: 897-901. (Pubitemid 46080185)
2. Aikawa M., Rabkin E., Sugiyama S., Voglic S.J., Fukumoto Y., Furukawa Y., Shiomi M., Schoen F.J., Libby P.: An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation, 2001; 103: 276-283. (Pubitemid 32095415)
3. Amorino G.P., Hoover R.L.: Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am. J. Pathol., 1998; 152: 199-207. (Pubitemid 28028060)
4. Arakaki P.A., Marques M.R., Santos M.C.: MMP-1 polymorphism and its relationship to pathological processes. J. Biosci., 2009; 34: 313-320.
5. Bassiouny H.S., Song R.H., Hong X.F., Singh A., Kocharyan H., Glagov S.: Flow regulation of 72-kD collagenase IV (MMP-2) after experimental arterial injury. Circulation, 1998; 98: 157-163. (Pubitemid 28317896)
6. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., Bernini F.: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol., 1998; 18: 1671-1678. (Pubitemid 28521054)
7. Beyzade S., Zhang S., Wong Y.K., Day I.N., Eriksson P., Ye S.: Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J. Am. Coll. Cardiol., 2003; 41: 2130-2137. (Pubitemid 36724257)
8. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., Meyer J., Cambien F., Tiret L., AtheroGene Investigators: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation, 2003; 107: 1579-1585. (Pubitemid 36397324)
9. Bode W., Reinemer P., Huber R., Kleine T., Schnierer S., Tschesche H.: The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J., 1994; 13: 1263-1269. (Pubitemid 24090206)
10. Brew K., Dinakarpandian D., Nagase H.: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta, 2000; 1477: 267-283. (Pubitemid 30119906)
11. Brown D.L., Hibbs M.S., Kearney M., Isner J.M.: Differential expression of 92-kDa gelatinase in primary atherosclerotic versus restenotic coronary lesions. Am. J. Cardiol., 1997; 79: 878-882. (Pubitemid 27197918)
12. Busti C., Falcinelli E., Momi S., Gresele P.: Matrix metalloproteinases and peripheral arterial disease. Intern. Emerg. Med., 2010; 5: 13-25.
13. Carmeliet P., Moons L., Ploplis V., Plow E., Collen D.: Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J. Clin. Invest., 1997; 99: 200-208. (Pubitemid 27053462)
14. Chesler N.C., Ku D.N., Galis Z.S.: Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am. J. Physiol., 1999; 277: H2002-H2009.
15. Cho A., Reidy M.A.: Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ. Res., 2002; 91: 845-851. (Pubitemid 35285083)
16. Cho H.J., Chae I.H., Park K.W., Ju J.R., Oh S., Lee M.M., Park Y.B.: Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percu-taneous coronary intervention. J. Hum. Genet., 2002; 47: 88-91. (Pubitemid 34296660)
17. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R.: The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol., 2008; 40: 1362-1378.
18. Corcoran M.L., Stetler-Stevenson W.G., Brown P.D., Wahl L.M.: Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. J. Biol. Chem., 1992; 267: 515-519.
19. Cuzner M.L., Gveric D., Strand C., Loughlin A.J., Paemen L., Opdenakker G., Newcombe J.: The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol., 1996; 55: 1194-1204. (Pubitemid 26397138)
20. Dean R.A., Cox J.H., Bellac C.L., Doucet A., Starr A.E., Overall C.M.: Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. Blood, 2008; 112: 3455-3464.
21. Deguchi J.O., Aikawa E., Libby P., Vachon J.R., Inada M., Krane S.M., Whittaker P., Aikawa M.: Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation, 2005; 112: 2708-2715. (Pubitemid 41532609)
22. Ferroni P., Basili S., Martini F., Cardarello C.M., Ceci F., Di Franco M., Bertazzoni G., Gazzaniga P.P., Alessandri C.: Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J. Investig. Med., 2003; 51: 295-300. (Pubitemid 37210891)
23. Forst T., Karagiannis E., Lübben G., Hohberg C., Schöndorf T., Dikta G., Drexler M., Morcos M., Dänschel W., Borchert M., Pfützner A.: Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis, 2008; 197: 311-317. (Pubitemid 351273253)
24. Galis Z.S., Asanuma K., Godin D., Meng X.: N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation, 1998; 97: 2445-2453. (Pubitemid 28278189)
25. Galis Z.S., Johnson C., Godin D., Magid R., Shipley J.M., Senior R.M., Ivan E.: Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ. Res., 2002; 91: 852-859. (Pubitemid 35285084)
26. Galt S.W., Lindemann S., Medd D., Allen L.L., Kraiss L.W., Harris E.S., Prescott S.M., McIntyre T.M., Weyrich A.S., Zimmerman G.A.: Differential regulation of matrix metalloproteinase-9 by monocytes adherent to collagen and platelets. Circ. Res., 2001; 89: 509-516. (Pubitemid 34132645)
27. Ghilardi G., Biondi M.L., DeMonti M., Turri O., Guagnellini E., Scorza R.: Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke, 2002; 33: 2408-2412.
28. Groblewska M., Mroczko B., Szmitkowski M.: Rola wybranych metaloproteinaz i ich inhibitorów w rozwoju raka jelita grubego. Postȩpy Hig. Med. Dośw., 2010; 64: 22-30.
29. Grzela T., Brawura-Biskupski-Samaha R., Jelenska M.M., Szmidt J.: Low molecular weight heparin treatment decreases MMP-9 plasma activity in patients with abdominal aortic aneurysm. Eur. J. Vasc. Endovasc. Surg., 2008; 35: 159-161. (Pubitemid 351163087)
30. Gu Z., Kaul M., Yan B., Kridel S.J., Cui J., Strongin A., Smith J.W., Liddington R.C., Lipton S.A.: S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science, 2002; 297: 1186-1190. (Pubitemid 36193354)
31. Halpert I., Sires U.I., Roby J.D., Potter-Perigo S., Wight T.N., Shapiro S.D., Welgus H.G., Wickline S.A., Parks W.C.: Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc. Natl. Acad. Sci. USA, 1996; 93: 9748-9753. (Pubitemid 26296680)
32. Hansson G.K., Libby P.: The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol., 2006; 6: 508-519. (Pubitemid 43980523)
33. Hartung H.P., Kieseier B.C.: The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol., 2000; 107: 140-147. (Pubitemid 30347419)
34. Hobeika M.J., Thompson R.W., Muhs B.E., Brooks P.C., Gagne P.J.: Matrix metalloproteinases in peripheral vascular disease. J. Vasc. Surg., 2007; 45: 849-857. (Pubitemid 46483940)
35. Hu J., Van den Steen P.E., Sang Q.X., Opdenakker G.: Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov., 2007; 6: 480-498. (Pubitemid 47064570)
36. Humphries S., Bauters C., Meirhaeghe A., Luong L., Bertrand M., Amouyel P.: The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur. Heart J., 2002; 23: 721-725. (Pubitemid 35230702)
37. Humphries S.E., Luong L.A., Talmud P.J., Frick M.H., Kesäniemi Y.A., Pasternack A., Taskinen M.R., Syvänne M.: The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. Atherosclerosis, 1998; 139: 49-56. (Pubitemid 28341866)
38. Isnard N., Legeais J.M., Renard G., Robert L.: Effect of hyaluronan on MMP expression and activation. Cell Biol. Int., 2001; 25: 735-739. (Pubitemid 32744562)
39. Jawień J.: New insights into immunological aspects of atherosclerosis. Pol. Arch. Med. Wewn., 2008; 118: 127-131. (Pubitemid 351488259)
40. Johnson J.L., George S.J., Newby A.C., Jackson C.L.: Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc. Natl. Acad. Sci. USA, 2005; 102: 15575-15580. (Pubitemid 41528098)
41. Johnson J.L., Jackson C.L., Angelini G.D., George S.J.: Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol., 1998; 18: 1707-1715. (Pubitemid 28521059)
42. Kenagy R.D., Nikkari S.T., Welgus H.G., Clowes A.W.: Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells. J. Clin. Invest., 1994; 93: 1987-1993. (Pubitemid 24143077)
43. Kunz J.: Initial lesions of vascular aging disease (arteriosclerosis). Gerontology, 2000; 46: 295-299.
44. Kunz J.: Matrix metalloproteinases and atherogenesis in dependence of age. Gerontology, 2007; 53: 63-73. (Pubitemid 46279732)
45. Kupai K., Szucs G., Cseh S., Hajdu I., Csonka C., Csont T., Ferdinandy P.: Matrix metalloproteinase activity assays: Importance of zymography. J. Pharmacol. Toxicol. Methods, 2010; 61: 205-209.
46. Lacraz S., Nicod L., Galve-de Rochemonteix B., Baumberger C., Dayer J.M., Welgus H.G.: Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J. Clin. Invest., 1992; 90: 382-388.
47. Lafleur M.A., Hollenberg M.D., Atkinson S.J., Knäuper V., Murphy G., Edwards D.R.: Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. Biochem. J., 2001; 357: 107-115. (Pubitemid 32642908)
48. Lambert E., Dassé E., Haye B., Petitfrere E.: TIMPs as multifacial proteins. Crit. Rev. Oncol. Hematol., 2004; 49: 187-198. (Pubitemid 38251351)
49. Lauhio A., Sorsa T., Srinivas R., Stenman M., Tervahartiala T., Stenman U.H., Grönhagen-Riska C., Honkanen E.: Urinary matrix metalloproteinase -8, -9, -14 and their regulators (TRY-1, TRY-2, TATI) in patients with diabetic nephropathy. Ann. Med., 2008; 40: 312-320. (Pubitemid 351563934)
50. Lees M., Taylor D.J., Woolley D.E.: Mast cell proteinases activate precursor forms of collagenase and stromelysin, but not of gelatinases A and B. Eur. J. Biochem., 1994; 223: 171-177. (Pubitemid 24221660)
51. Li L., Akers K., Eisen A.Z., Seltzer J.L.: Activation of gelatinase A (72-kDa type IV collagenase) induced by monensin in normal human fibroblasts. Exp. Cell Res., 1997; 232: 322-330. (Pubitemid 27194045)
52. Li L., Renier G.: The oral anti-diabetic agent, gliclazide, inhibits oxidized LDL-mediated LOX-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells. Atherosclerosis, 2009; 204: 40-46.
53. Lijnen H.R.: Plasmin and matrix metalloproteinases in vascular remodeling. Thromb. Haemost., 2001; 86: 324-333. (Pubitemid 32663963)
54. Lijnen H.R., Van Hoef B., Vanlinthout I., Verstreken M., Rio M.C., Collen D.: Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. Arterioscler. Thromb. Vasc. Biol., 1999; 19: 2863-2870. (Pubitemid 30029811)
55. Lipka D., Boratyński J.: Metaloproteinazy MMP. Struktura i funkcja. Postȩpy Hig. Med. Dośw., 2008; 62: 328-336.
56. Liu P., Sun M., Sader S.: Matrix metalloproteinases in cardiovascular disease. Can. J. Cardiol., 2006; 22(Suppl.B): 25B-30B. (Pubitemid 44963568)
57. Luan Z., Chase A.J., Newby A.C.: Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol., 2003; 23: 769-775. (Pubitemid 36566165)
58. Luttun A., Lutgens E., Manderveld A., Maris K., Collen D., Carmeliet P., Moons L.: Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against athe-rosclerotic media destruction but differentially affects plaque growth. Circulation, 2004; 109: 1408-1414. (Pubitemid 38387828)
59. Mallat Z., Tedgui A.: Cytokines as regulators of atherosclerosis in murine models. Curr. Drug Targets, 2007; 8: 1264-1272.
60. Mangge H., Hubmann H., Pilz S., Schauenstein K., Renner W., März W.: Beyond cholesterol - inflammatory cytokines, the key mediators in atherosclerosis. Clin. Chem. Lab. Med., 2004; 42: 467-474. (Pubitemid 38779746)
61. Marx N., Froehlich J., Siam L., Ittner J., Wierse G., Schmidt A., Scharnagl H., Hombach V., Koenig W.: Antidiabetic PPAR γ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 2003; 23: 283-288. (Pubitemid 36231941)
62. Marx N., Sukhova G., Murphy C., Libby P., Plutzky J.: Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am. J. Pathol., 1998; 153: 17-23. (Pubitemid 28317502)
63. Matias-Román S., Gálvez B.G., Genis L., Yánez-Mó M., de la Rosa G., Sánchez-Mateos P., Sánchez-Madrid F., Arroyo A.G.: Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. Blood, 2005; 105: 3956-3964. (Pubitemid 40656143)
64. Morgan A.R., Zhang B., Tapper W., Collins A., Ye S.: Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J. Mol. Med., 2003; 81: 321-326. (Pubitemid 36718329)
65. Nagase H., Visse R., Murphy G.: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res., 2006; 69: 562-573. (Pubitemid 43139720)
66. Newby A.C.: Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol. Rev., 2005; 85: 1-31. (Pubitemid 40171256)
67. Newby A.C.: Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler. Thromb. Vasc. Biol., 2008; 28: 2108-2114.
68. Niedźwiedzka-Rystwej P., Mȩkal A., Deptuła W.: Komórki układu odpornościowego w miażdżycy - wybrane dane. Postȩpy Hig. Med. Dośw., 2010; 64: 417-422.
69. Orbe J., Fernandez L., Rodriguez J.A., Rábago G., Belzunce M., Monasterio A., Roncal C., Páramo J.A.: Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis, 2003; 170: 269-276. (Pubitemid 37377799)
70. Peeters W., Hellings W.E., de Kleijn D.P., de Vries J.P., Moll F.L., Vink A., Pasterkamp G.: Carotid atherosclerotic plaques stabilize after stroke: insights into the natural process of atherosclerotic plaque stabilization. Arterioscler. Thromb. Vasc. Biol., 2009; 29: 128-133.
71. Peppin G.J., Weiss S.J.: Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. Proc. Natl. Acad. Sci. USA, 1986; 83: 4322-4326. (Pubitemid 16057042)
72. Prall A.K., Longo G.M., Mayhan W.G., Waltke E.A., Fleckten B., Thompson R.W., Baxter B.T.: Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J. Vasc. Surg., 2002; 35: 923-929.
73. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., Galis Z.S.: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest., 1996; 98: 2572-2579. (Pubitemid 26415078)
74. Rauch B.H., Bretschneider E., Braun M., Schrör K.: Factor Xa releases matrix metalloproteinase-2 (MMP-2) from human vascular smooth muscle cells and stimulates the conversion of pro-MMP-2 to MMP-2: role of MMP-2 in factor Xa-induced DNA synthesis and matrix invasion. Circ. Res., 2002; 90: 1122-1127. (Pubitemid 34627912)
75. Rodriguez-Feo J.A., Sluijter J.P., de Kleijn D.P., Pasterkamp G.: Modulation of collagen turnover in cardiovascular disease. Curr. Pharm. Des., 2005; 11: 2501-2514. (Pubitemid 40872694)
76. Ross R.: Atherosclerosis - an inflammatory disease. N. Engl. J. Med., 1999; 340: 115-126. (Pubitemid 29054847)
77. Sakamoto K., Murata T., Chuma H., Hori M., Ozaki H.: Fluvastatin prevents vascular hyperplasia by inhibiting phenotype modulation and proliferation through extracellular signal-regulated kinase 1 and 2 and p38 mitogen-activated protein kinase inactivation in organ-cultured artery. Arterioscler. Thromb. Vasc. Biol., 2005; 25: 327-333. (Pubitemid 40189153)
78. Salowe S.P., Marcy A.I., Cuca G.C., Smith C.K., Kopka I.E., Hagmann W.K., Hermes J.D.: Characterization of zinc-binding sites in human stromelysin-1: stoichiometry of the catalytic domain and identification of a cysteine ligand in the proenzyme. Biochemistry, 1992; 31: 4535-4540.
79. Samnegard A., Silveira A., Lundman P., Boquist S., Odeberg J., Hulthe J., McPheat W., Tornvall P., Bergstrand L., Ericsson C.G., Hamsten A., Eriksson P.: Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 -1612 5A/6A promoter genotype and associated with myocardial infarction. J. Intern. Med., 2005; 258: 411-419. (Pubitemid 41546556)
80. Sampieri C.L., Nuttall R.K., Young D.A., Goldspink D., Clark I.M., Edwards D.R.: Activation of p38 and JNK MAPK pathways abrogates requirement for new protein synthesis for phorbol ester mediated induction of select MMP and TIMP genes. Matrix Biol., 2008; 27: 128-138. (Pubitemid 351221010)
81. Sang Q.X., Birkedal-Hansen H., Van Wart H.E.: Proteolytic and non-proteolytic activation of human neutrophil progelatinase B. Biochim. Biophys. Acta, 1995; 1251: 99-108.
82. Sariahmetoglu M., Crawford B.D., Leon H., Sawicka J., Li L., Ballermann B.J., Holmes C., Berthiaume L.G., Holt A., Sawicki G., Schulz R.: Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J., 2007; 21: 2486-2495. (Pubitemid 47230678)
83. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., Seiki M.: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature, 1994; 370: 61-65. (Pubitemid 24216953)
84. Schieffer B., Bunte C., Witte J., Hoeper K., Böger R.H., Schwedhelm E., Drexler H.: Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J. Am. Coll. Cardiol., 2004; 44: 362-368. (Pubitemid 38960662)
85. Schmidt R., Redecke V., Breitfeld Y., Wantia N., Miethke T., Massberg S., Fischel S., Neumann F.J., Schömig A., May A.E.: EMMPRIN (CD 147) is a central activator of extracellular matrix degradation by Chlamydia pneumoniae-infected monocytes. Implications for plaque rupture. Thromb. Haemost., 2006; 95: 151-158.
86. Schönbeck U., Mach F., Sukhova G.K., Atkinson E., Levesque E., Herman M., Graber P., Basset P., Libby P.: Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J. Exp. Med., 1999; 189: 843-853. (Pubitemid 29189689)
87. Senokuchi T., Matsumura T., Sakai M., Yano M., Taguchi T., Matsuo T., Sonoda K., Kukidome D., Imoto K., Nishikawa T., Kim-Mitsuyama S., Takuwa Y., Araki E.: Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway. J. Biol. Chem., 2005; 280: 6627-6633. (Pubitemid 40341214)
88. Silence J., Lupu F., Collen D., Lijnen H.R.: Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler. Thromb. Vasc. Biol., 2001; 21: 1440-1445. (Pubitemid 34219805)
89. Sithu S.D., English W.R., Olson P., Krubasik D., Baker A.H., Murphy G., D'Souza S.E.: Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration. J. Biol. Chem., 2007; 282: 25010-25019. (Pubitemid 47347548)
90. Spinale F.G.: Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev., 2007; 87: 1285-1342. (Pubitemid 350041472)
91. Spinale F.G., Coker M.L., Heung L.J., Bond B.R., Gunasinghe H.R., Etoh T., Goldberg A.T., Zellner J.L., Crumbley A.J.: A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation, 2000; 102: 1944-1949.
92. Stawowy P., Meyborg H., Stibenz D., Borges Pereira Stawowy N., Roser M., Thanabalasingam U., Veinot J.P., Chrétien M., Seidah N.G., Fleck E., Graf K.: Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase-pro-matrix metalloproteinase-2 proteolytic cascade in atherosclerosis. Circulation, 2005; 111: 2820-2827. (Pubitemid 40791555)
93. Tayebjee M.H., Lip G.Y., Blann A.D., Macfadyen R.J.: Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb. Res., 2005; 115: 205-210. (Pubitemid 40029677)
94. Tayebjee M.H., Tan K.T., MacFadyen R.J., Lip G.Y.: Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J. Intern. Med., 2005; 257: 110-116. (Pubitemid 40129132)
95. Tziakas D.N., Chalikias G.K., Parissis J.T., Hatzinikolaou E.I., Papadopoulos E.D., Tripsiannis G.A., Papadopoulou E.G., Tentes I.K., Karas S.M., Chatseras D.I.: Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int. J. Cardiol., 2004; 94: 269-277. (Pubitemid 38490672)
96. Van den Steen P.E., Opdenakker G., Wormald M.R., Dwek R.A., Rudd P.M.: Matrix remodelling enzymes, the protease cascade and glycosylation. Biochim. Biophys. Acta, 2001; 1528: 61-73. (Pubitemid 33001266)
97. Visse R., Nagase H.: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res., 2003; 92: 827-839. (Pubitemid 36542523)
98. Wang J., Warzecha D., Wilcken D., Wang X.L.: Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin. Sci., 2001; 101: 87-92. (Pubitemid 32634742)
99. Williams J.K., Sukhova G.K., Herrington D.M., Libby P.: Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J. Am. Coll. Cardiol., 1998; 31: 684-691. (Pubitemid 28144138)
100. Wu T.C., Leu H.B., Lin W.T., Lin C.P., Lin S.J., Chen J.W.: Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur. J. Clin. Invest., 2005; 35: 537-545. (Pubitemid 41243296)
101. Yamamoto D., Takai S., Miyazaki M.: Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. Eur. J. Pharmacol., 2008; 588: 277-279.
102. Yan C., Boyd D.D.: Regulation of matrix metalloproteinase gene expression. J. Cell. Physiol., 2007; 211: 19-26. (Pubitemid 46363892)
103. Yu Y., Koike T., Kitajima S., Liu E., Morimoto M., Shiomi M., Hatakeyama K., Asada Y., Wang K.Y., Sasaguri Y., Watanabe T., Fan J.: Temporal and quantitative analysis of expression of metalloproteinases (MMPs) and their endogenous inhibitors in atherosclerotic lesions. Histol. Histopathol., 2008; 23: 1503-1516.
104. Zeng B., Prasan A., Fung K.C., Solanki V., Bruce D., Freedman S.B., Brieger D.: Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern. Med. J., 2005; 35: 331-335. (Pubitemid 40826856)
105. Zhang B., Ye S., Herrmann S.M., Eriksson P., de Maat M., Evans A., Arveiler D., Luc G., Cambien F., Hamsten A., Watkins H., Henney A.M.: Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 1999; 99: 1788-1794. (Pubitemid 29181405)